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Imatinib mesylate is a small molecule used in cancer therapy as a thyrosine kinase inhibitor. 
Dexketoprofen trometamol is a non-steroidal anti-inflammatory drug that has seen use in cancer 
therapy in combination with an anticancer drug to minimize tumor size and to reduce pain in patients. 
In the present study, imatinib mesylate and dexketoprofen trometamol were selected as potential 
model drugs to be used in combination. A new, simple and selective Ultra Performance Liquid 
Chromatography method was developed and validated to determine the drug substances in distilled 
water, in a pH 7.4 phosphate buffer and in Dulbecco’s Modified Eagle Medium. The proposed method 
was developed using a BEH C-18 column with isocratic elution. A mixture of methanol:acetonitrile 
(80:20, v/v) and pH 9.5, 0.05 M ammonium acetate were (70:30, v/v) used as a mobile phase. Detection 
was carried out with a flow rate of 0.3 mL/min, a column temperature of 30°C and an injection volume 
of 20 µL. The method was validated considering linearity, accuracy, precision, specificity, robustness, 
detection limit and quantitation limit values, and was found to be linear in a range from 0.05 to 20.0 
µg/mL for the three different media.
Keywords: Imatinib mesylate. Dexketoprofen trometamol. Ultra Performance Liquid 
Chromatography. Dulbecco’s Modified Eagle Medium.
INTRODUCTION
In pharmacy, toxicology and clinical analysis, 
the determination or assay of a drug substance has a 
great importance in terms of increasing productivity 
and reducing costs. Shortening the analysis time 
requires shortening column length, increasing flow rate, 
reducing the particle size of the column and increasing 
temperature. These approaches, however, come with 
various risks when applied to HPLC devices. For 
example, when a short and small particle sized column 
is used, the compounds in the sample may not always 
sufficiently separated, column efficiency may be reduced 
and high back pressure can be produced (Nováková, 
Solichová and Solich, 2006). Ultra Performance Liquid 
Chromatography (UPLC) was developed to overcome 
all these problems, allowing the separation of small 
molecules, leading to uniquely superior performance 
with significant improvements in resolution, sensitivity 
and speed (Antil et al., 2013). In comparison with the 
HPLC method, it comes with a reduced analysis time 
and provides better separation (Gumustas et al., 2013). 
Dexketoprofen trometamol (DEX) is a water-soluble 
salt form of dextrorotatory and an S(+) enantiomer of 
ketoprofen, which is a non-steroidal anti-inflammatory 
drug (NSAID). It has been used as a non-selective 
cyclooxygenase (COX) enzyme inhibitor (Miranda et al., 
2011; Herrero et al., 2003). Racemic ketoprofen is also 
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used for analgesic and anti-inflammatory effects (Figure 
1), although this effect can be observed mainly due to 
dexketoprofen, as the R(-) enantiomer is not associated 
with any such activity (Miranda et al., 2011). The free 
acid form is almost insoluble in water, but soluble in 
organic solvents such as chloroform, ether and ethanol, 
while the tromethamine salt is freely soluble in water as 
well as in organic solvents (Chandrasekharan, 2007).
Imatinib mesylate (IMA) is a potent and selective 
inhibitor of protein tyrosine kinase Bcr-Alb, platelet-
derived growth factor and c-KIT (Figure 2). The drug 
was approved by the FDA for the treatment of chronic 
mylegeneous leukemia and gastrointestinal stromal 
tumors in 2001 and 2002 (FDA Consum. 2001; FDA 
Consum. 2002), respectively. In addition, it has started 
to be used for the treatment of different types of cancer 
(Ma, Xu, Shou, 2009; Cohen, Moses, Pazdur, 2002). 
For example, the dermatofibrosarcoma protuberans, 
aggressive fibromatoses, malignant melanoma and 
chordoma forms of cancer have all been treated with IMA 
(Iqbal, Igbal, 2014). The active ingredient is an off-white 
to yellowish crystalline powder that is highly soluble in 
water, although the solubility of the drug is dependent 
on pH, with solubility decreasing with increasing pH 
(Novartis Pharmaceutical Corporation, 2017).
FIGURE 1 - The chemical structure of dexketoprofen 
trometamol.
Epidemiological studies have indicated that the 
use of NSAIDs reduces the risk of the development of 
such fatal cancers as colorectal cancer. Since the COX-
2 enzyme is responsible for increased prostaglandin 
production in inflammatory and neoplastic tissues, it 
continues to affect COX-2 during the treatment of cancer 
(Dannenberg et al., 2001). It has also been observed that 
IMA increases COX-2 expression, and as a result, the 
development of resistance to IMA over time has been 
reported as possible (Atari-Hajipirloo et al., 2016). Recent 
studies have shown that the COX enzyme has become a 
target for the prevention of cancer. Many studies related 
to the use of combinations of NSAIDs with anticancer 
drugs can be found in literature as a new approach to 
the treatment of cancer (Liu et al., 2017; Pan et al., 2007; 
Mohammed et al., 2003). Due to the positive results 
obtained from cell culture studies, dosage forms such 
as liposome and polymeric nanoparticles containing 
anticancer drug and NSAID in combination have also 
been developed (Gowda et al., 2017; Singh, 2018).
 
FIGURE 2 - The chemical structure of imatinib mesylate.
Various characterization studies into such topics as 
encapsulation efficiency, in vitro dissolution rate and ex 
vivo cell diffusion have been carried out on the developed 
formulations. The amount of drug in the formulation or 
releasing the drug to the medium need be calculated 
(Yue et al., 2009; Miao et al., 2015; Mutlu-Ağardan et 
al., 2016). For this reason, an analytical method specific 
to the drug should be developed for different media, 
such as distilled water, a pH 7.4 phosphate buffer, 
which seen use in dissolution studies, and Dulbecco’s 
Modified Eagle Medium (DMEM), which has been used 
as a medium in cell culture studies. These media are 
preferred in the present study due to their recent use in 
the literature, especially in drug development studies. 
Distilled water was used as a dissolution medium in 
in vitro dissolution studies during the formulation 
development period. The pH 7.4 phosphate buffer 
is another frequently used dissolution medium. In 
formulation development studies, cell culture studies are 
particularly important, and DMEM has been also seen 
frequent use as a cell culture medium in such studies 
(Kumari et al., 2018; Reed et al., 2012). In previous 
literature, many liquid chromatography methods for 
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IMA and DEX are available in several media, although 
there is as yet no chromatographic method for the 
simultaneous determination of IMA and DEX (Ivanovic 
et al., 2004; Moreno et al., 2013; Archana, Vikas, 2013; 
İlbasmış-Tamer, 2017).
Combinations of anticancer drugs and NSAID have 
proven to be superior to monotherapies, and so there is 
an apparent need in the future for a proper method of 
analysis for these drugs in various media in combination 
for formulation development, quality control or other 
purposes. IMA has been used in cancer therapy and DEX 
is a potent NSAID, and it is clear that a combination of 
the two will be formulated soon. In present study, DEX, 
which is an NSAID, and IMA, which is an anticancer 
agent, have been chosen as the model drugs in an 
attempt to develop a UPLC method for the simultaneous 
analysis of these drugs in various media. For the present 
study, three different media were used: distilled water 
(for encapsulation efficiency), pH 7.4 phosphate buffer 




Analytical grade methanol (≥99.8%, Sigma, 
Germany), acetonitrile (≥99.93%, Sigma, Germany), 
an ammonium hydroxide solution (≥25-30%, Sigma, 
Germany) and ammonium acetate (Merck, Germany) 
were used in this study for the preparation of the mobile 
phase. The IMA was supplied by Biotang (USA); the 
DEX and potassium dihydrogen phosphate (99.995%) 
were purchased from Sigma-Aldrich (Germany); the 
DMEM was supplied from Lonza (Belgium); and the 
Bi-distilled water was prepared using a Barnstead water 
purification system (Barnstead, USA).
Analytical and chromatographic conditions
A UPLC system (Waters Acquity UPLC) with 
Empower software, equipped with a binary solvent 
pump, a photo diode array detector and BEH C-18 
column (100x2.1 mm, 1.7 µm particle size, Acquity, 
Waters, Ireland) were used. An ultrasonic bath was used 
for the degassing of the solvent systems. A variety of 
mobile phases were tested during the development stage 
of the method for the simultaneous analysis of DEX and 
IMA. A mixture of methanol:acetonitrile (80:20, v/v) 
and 0.05 M ammonium acetate (pH 9.5 adjusted with 
ammonium hydroxide) (70:30, v/v) was found to be the 
most suitable mobile phase. The flow rate of the mobile 
phase and the injection volume of the sample were set 
to 0.3 mL/min and 20 µL, respectively. The column 
temperature was maintained at 30 °C. The detection 
of the drug was carried out at 258 nm for the distilled 
water and pH 7.4 phosphate buffer media, and 326 nm 
for DMEM. The total run time was 3 minutes. 
Preparation of mobile phase, stock 
solution and samples
For the preparation of the mobile phase, ammonium 
acetate (0.964 g) was dissolved in 250 mL distilled 
water in a volumetric flask and the pH of the solution 
was adjusted to 9.5 with ammonium hydroxide.
Stock solutions and samples were prepared as 
follows: DEX (10 mg) and IMA (10 mg) were transferred 
into volumetric flask and filled up to 100 mL with 
distilled water, along with the pH 7.4 phosphate buffer 
or DMEM. The flask was stirred until all ingredients 
were dissolved. The final concentration of the stock 
solution was 100 µg/mL. Different volumes of the stock 
solution were transferred to other 10 mL volumetric 
flasks and filled up to the desired volumes with the 
media. The mobile phase and all other solutions were 
filtered through a filter paper (0.22 µm pore size) prior 
to the analysis. In this way, calibration samples were 
obtained with a concentration range of 0.05 to 20 µg/mL. 
The calibration curves were then obtained by plotting 
the peak area against the concentration of drug. Each 
concentration was analyzed in six replicates.
Validation of the analytical method
The validation studies were carried out based 
on the International Conference on Harmonisation 
(ICH) Validation of Analytical Procedures: Text and 
methodology Q2(R1). The validation parameters, which 
were indicated in the guideline, were linearity, accuracy, 
precision (repeatability and intermediate precision), 
specificity, robustness, detection limit and quantitation 
limit (ICH, 2005).
RESULTS AND DISCUSSION
The UPLC proposed in the present study is new, 
and is appropriate for the simultaneous determination of 
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DEX and IMA. The novelty of the method was confirmed 
through a detailed literature search, which revealed 
no studies of such a simultaneous determination. The 
search did, however, reveal some HPLC and UPLC 
methods for the individual analyses of DEX or IMA in 
a phoshate buffer or plasma (Rezende, 2013; Sahoo1, 
2015), while no method was identified in literature for 
DMEM for these substances. For instance, one HPLC 
method that was successfully validated was found to 
be useful for the measurement of IMA concentrations 
in samples from chronic myeloid leukemia patients to 
check for treatment compliance (Rezende, 2013). Other 
methods were reported to be useful and being validated 
in literature for DEX. Although a few sucessfuly 
validated methods have been published for individual 
analyses of DEX or IMA, none were found to be directly 
comparable with the method proposed in the present 
study (İlbasmış-Tamer, 2017; Mulla, 2011).
Optimization of chromatographic conditions
To achieve optimal chromatographic separation, 
different mobile phases and flow rates were tested. 
Various buffer systems and mobile phases (e.g. 
potassium dihydrogen phosphate buffers with different 
molarity, formic acid of different percentages in water 
or methanol, and various organic solvent systems 
with different pH values) were also used to develop 
the analysis method for IMA and DEX. However, 
the symmetric and sharp peaks of IMA at the initial 
part of UPLC method development studies could not 
obtained. According to the study by Nageswari, Reddy 
and Mukkanti (2012), reported chromatographic 
conditions were modified. The proposed method was 
developed using a BEH C-18 column with isocratic 
elutions. A mixture of methanol:acetonitrile (80:20, 
v/v) and pH 9.5, 0.05 M ammonium acetate was 
used in a 70:30 v/v ratio as a mobile phase. Various 
mobile phases were used to obtain a good separation. 
For example, various buffer systems and mixtures 
of organic solvents, such as methanol/acetonitrile 
with water at various ratios, were tested, but the most 
successful and satisfactory results were obtained 
with a pH 9.5 acetate buffer. The chromatographic 
conditions were a flow rate of 0.3 mL/min, a column 
temperature of 30 °C and an injection volume of 
20 µL. As a result, for both IMA and DEX, smooth, 
sharp and symmetrical peaks were obtained. Validation 
studies were performed on an Agilent Waters UPLC 
system with Empower software, and the method was 
validated according to ICH(Q2) guidelines (linearity, 
accuracy, precision, specificity and robustness, limit 
of detection (LOD) and limit of quantification (LOQ) 
values were calculated). 
Parameters of validation
In line with the method mentioned above, six 
parallel studies were carried out for IMA and DEX for 
each medium, with linearity evaluated first. Samples 
with concentrations ranging from 0.05 to 20 µg/mL 
were prepared, and the peak area of drug substances 
corresponding to the concentration of drug substances 
was plotted (Figure 3, Figure 4 and Figure 5).
The accuracy of a measurement system is defined 
as the degree of closeness of the measurements to 
the real value. Samples with known concentrations 
were analyzed for accuracy with three working level 
concentrations. Accordingly, 80, 100 and 120% of the 
expected concentrations of analyte in the sample was 
calculated separately for each medium (Table I and 
Table II).
Precision is related to reproducibility and 
repeatability, which can be calculated after repeated 
measurements under unchanging conditions. System 
precision is evaluated from standard deviation (SD) and 
relative standard deviation (RSD). Intra-day precision 
the samples were prepared (10 µg/mL) and injected 
into system 10 times, while inter-day precision was 
determined by analyzing the same samples on three 
different days. The results of the intra-day and inter-day 
precisions are presented in the tables (Table III, Table 
IV, Table V and Table VI). 
The applied method must detect only the desired 
drug substance, both specifically and selectively. In 
a tested formulation, other substances should not give 
any peak at the same retention time, and this must be 
checked. The developed method was shown to be specific 
for IMA and DEX, since the peaks of drug substance 
were observed on the chromatogram at different 
retention times (Figure 6, Figure 7 and Figure 8) and 
no interference was observed from any other substance.
For the developed analytical method, robustness 
studies should also be performed to ensure that 
measurements are not affected by minor experimental 
changes. For example, the stability of analytical solutions, 
extraction time, pH value of the mobile phase, mobile 
phase component ratios or column can be considered 
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as minor variations. In this study, the stability of the 
analytical solutions at various temperatures and times 
were investigated by calculating the percentage of the 
remaining DEX and IMA (after 72 hours at 4, 25 and 
37 °C). There was no significant differences p>0.05 
(Table VII). 
FIGURE 3 - The calibration curves of imatinib mesylate and dexketoprofen trometamol in distilled water (n=6).
FIGURE 4 - The calibration curves of imatinib mesylate and dexketoprofen trometamol in phosphate buffer (n=6).
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FIGURE 5 - The calibration curves of imatinib mesylate and dexketoprofen trometamol in DMEM (n= 6).
TABLE I - Accuracy and recovery report of imatinib mesylate
Percentage level 
(%)
Concentration of IMA in 
solution  
(µg/mL)





120 12 12.100±0.029 0.239
100 10 10.040±0.006 0.058
80 8 8.140±0.031 0.386
pH 7.4 Phosphate Buffer
120 12 12.434±0.077 0.619
100 10 10.291±0.027 0.263
80 8 8.055±0.023 0.284
DMEM
120 12 12.004±0.050 0.414
100 10 9.999±0.002 0.021
80 8 7.998±0.019 0.236
IMA is imatinib mesylate. Conc. is concentration. DMEM is Dulbecco’s Modified Eagle Medium. SD is standard deviation and 
RSD is relative standard deviation (n=3).
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TABLE II - Accuracy and recovery report of dexketoprofen trometamol
Percentage level 
(%)







120 12 11.911 ± 0.007 0.061
100 10 10.012 ± 0.014 0.136
80 8 8.032 ± 0.007 0.090
pH 7.4 Phosphate 
Buffer
120 12 12.213 ± 0.015 0.120
100 10 10.071 ± 0.007 0.071
80 8 7.932 ± 0.004 0.050
DMEM
120 12 12.263 ± 0.093 0.757
100 10 10.166 ± 0.080 0.785
80 8 8.070 ± 0.056 0.694
DEX is dexketoprofen trometamol. Conc. is concentration. DMEM is Dulbecco’s Modified Eagle Medium. SD is standard 
deviation and RSD is relative standard deviation (n=3).
TABLE III - Intra-day precision for imatinib mesylate










20 20.067 20 20.159 20 19.949
20 20.088 20 20.120 20 19.951
20 20.020 20 20.129 20 19.949
20 20.090 20 20.127 20 19.948
20 20.014 20 20.139 20 19.946
20 20.029 20 20.124 20 19.943
20 20.010 20 20.133 20 19.934
20 20.088 20 20.130 20 19.943
(continuing)
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TABLE III - Intra-day precision for imatinib mesylate










20 20.013 20 20.095 20 19.926
20 20.071 20 20.028 20 19.914
Mean 20.049 Mean 20.118 Mean 19.940
SD 0.202 SD 0.036 SD 0.120
RSD% 0.981 RSD% 0.177 RSD% 0.619
DMEM is Dulbecco’s Modified Eagle Medium. SD is standard deviation and RSD is relative standard deviation (n=10).
TABLE IV - Intra-day precision for dexketoprofen trometamol











10 10.011 10 10.135 10 10.445
10 10.021 10 10.128 10 10.448
10 10.034 10 10.125 10 10.433
10 10.027 10 10.124 10 10.433
10 10.018 10 10.143 10 10.426
10 10.033 10 10.127 10 10.420
10 10.036 10 10.135 10 10.407
10 10.040 10 10.141 10 10.397
10 10.048 10 10.136 10 10.394
10 10.038 10 10.136 10 10.386
Mean 10.031 Mean 10.133 Mean 10.419
SD 0.011 SD 0.007 SD 0.022
RSD% 0.112 RSD% 0.066 RSD% 0.216
DMEM is Dulbecco’s Modified Eagle Medium. SD is standard deviation and RSD is relative standard deviation (n=10).
Development and validation of highly selective method for the determination of imatinib mesylate and dexketoprofen trometamol combination in three 
different media
Braz. J. Pharm. Sci. 2020;56: e18583 Page 9/14
TABLE V - Inter-day precision for imatinib mesylate
Concentration
(µg/mL)
1.day 2. day 3. day Mean SD RSD%
Distilled water
20 19.977 19.975 19.968 19.974 0.047 0.239
5 5.015 5.014 5..004 5.011 0.059 1.147
1 0.994 0.996 0.996 0.996 0.010 1.069
0.2 0.196 0.196 0.196 0.196 0.001 0.923
pH 7.4 Phosphate 
Buffer
20 19.964 20.069 19.899 19.977 0.086 0.430
5 4.834 4.900 4.929 4.888 0.049 0.993
1 0.944 0.945 0.924 0.938 0.012 1.275
0.2 0.216 0.221 0.218 0.218 0.003 1.266
DMEM
20 20.019 20.019 20.023 20.020 0.026 0.127
5 4.979 4.979 4.978 4.979 0.001 0.107
1 0.997 0.997 0.997 0.997 0.001 0.156
0.2 0.204 0.204 0.204 0.204 0.002 0.098
DMEM is Dulbecco’s Modified Eagle Medium. SD is standard deviation and RSD is relative standard deviation (n=3).
TABLE VI - Inter-day precision for dexketoprofen trometamol
Concentration
(µg/mL)
1.day 2. day 3. day Mean SD RSD%
Distilled water
10 10.034 10.046 10.024 10.035 0.011 0.110
2 1.963 1.965 1.963 1.964 0.001 0.065
0.5 0.487 0.487 0.488 0.487 0.001 0.185
0.09 0.087 0.087 0.086 0.087 0.000 0.381
pH 7.4 Phosphate 
Buffer
10 9.947 9.890 9.840 9.892 0.053 0.541
2 2.018 2.004 2.011 2.011 0.007 0.358
0.5 0.499 0.503 0.496 0.499 0.004 0.713
0.1 0.094 0.094 0.093 0.093 0.001 0.804
(continuing) 
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TABLE VI - Inter-day precision for dexketoprofen trometamol
Concentration
(µg/mL)
1.day 2. day 3. day Mean SD RSD%
DMEM
10 10.254 10.263 10.085 10.201 0.100 0.984
2 1.984 2.024 2.002 2.004 0.020 0.999
0.5 0.465 0.468 0.477 0.470 0.006 1.306
0.05 0.051 0.051 0.051 0.051 0.000 0.821
DMEM is Dulbecco’s Modified Eagle Medium. SD is standard deviation and RSD is relative standard deviation (n=3).
FIGURE 6 - UPLC chromatogram of dexketoprofen trometamol and imatinib mesylate in distilled water.
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FIGURE 7 - UPLC chromatogram of dexketoprofen trometamol and imatinib mesylate in phosphate buffer.
FIGURE 8 - UPLC chromatogram of dexketoprofen trometamol and imatinib mesylate in DMEM.
Ozlem Coban, Zelihagul Degim
Page 12/14 Braz. J. Pharm. Sci. 2020;56: e18583
TABLE VII - P-values of remained DEX and IMA in solutions for robustness
Distilled water pH 7.4 Phosphate Buffer DMEM
4 °C 25 °C 37 °C 4 °C 25 °C 37 °C 4 °C 25 °C 37 °C
IMA 0.909 0.076 0.065 0.391 0.391 0.103 0.423 0.085 0.126
DEX 0.215 0.080 0.066 0.441 0.431 0.080 0.415 0.078 0.113
P > 0.05, level of significance.
LOD is the lowest quantity of analyte in a sample 
that can be detected, but not certainly quantified while 
LOQ is the lowest quantity of analyte in a sample in which 
the quantity of analyte can be determined as an absolute 
value. Both can be calculated based on the standard 
deviation of the response and the slope (ICH, 2005). The 
results are presented in Table VIII and Table IX.
The validation parameters were obtained from various 
repeated studies (number of replicates shown in brackets 
for each result). The results were given as mean±standard 
deviation, and the calibration curve of the analytical 
method was obtained considering concentrations versus 
peak areas. A quite high correlation was obtained 
(r2:0.999 for both of samples in each medium) with 
the concentration range of 0.05–20 µg/mL in the three 
different media for DEX and IMA. The concentrations of 
10 µg/mL DEX and IMA were used to test the accuracy of 
the method, for which 80% and 120% concentrations were 
prepared, and all samples were analyzed. The amounts of 
DEX and IMA in these solutions were determined using 
the proposed method, and the accuracy of the methods 
was found to be within the acceptable range. System 
precision was calculated also for the ten samples, while 
intermediate precision was determined by analyzing the 
samples on different days. The precision values were 
found to be suitable. A simultaneous analysis of IMA and 
DEX showed that the method is specific for both drug 
substances, in that the peaks of the analytes were observed 
at different retention times, and these peaks were far away 
from the peak of the solvent on the chromatogram. In 
the robustness studies, the samples were kept at various 
temperatures and compared with the initial values,  and no 
significant difference was observed between the groups 
(P> 0.05). The LOQ and LOD for DEX and IMA were 
found to be suitable. For all parameters, RSD values were 
lower than 2%.
TABLE VIII - Limit of detection and limit of quantitation 







LOQ (µg/mL) 0.014 0.037 0.012
LOD (µg/mL) 0.005 0.012 0.004
DMEM is Dulbecco’s Modified Eagle Medium. LOQ is limit 
of quantification. LOD is limit of detection.








LOQ (µg/mL) 0.006 0.013 0.038
LOD (µg/mL) 0.002 0.004 0.013
DMEM is Dulbecco’s Modified Eagle Medium. LOQ is limit 
of quantification. LOD is limit of detection.
CONCLUSION
A rapid, isocratic UPLC method was developed for 
quantitative simultaneous analysis of DEX and IMA. 
The method was found to be precise, accurate, linear 
and fast. This method may be useful for researchers 
interested in carrying out in vitro and ex vivo studies, 
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such as quantification, dissolution, stability and cell 
culture studies, with IMA, DEX, or a combination of 
the two.
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